Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.59 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.59 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.59 |
| ▸ | GJA1 | P17302 | 1/20 | 0.54 |
| ▸ | GJB2 | P29033 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | IGF2R | P11717 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9418216 | 1.00 | MEN1 (0.61) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL8021036 | 1.00 | MEN1 (0.61) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL8718351 | 1.00 | MEN1 (0.61) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL16212290 | 1.00 | MEN1 (0.61) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL20243556 | 1.00 | MEN1 (0.61) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL15712987 | 1.00 | MEN1 (0.61) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL9418205 | 1.00 | MEN1 (0.61) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL670601 | 1.00 | MEN1 (0.61) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL19334968 | 1.00 | MEN1 (0.61) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL363874 | 1.00 | MEN1 (0.61) | MEN1KMT2ALGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505795-B2 | Method for producing scyllo-inositol | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-11-29 | — | — | US | disclosed |
| US-20160194667-A1 | Method for Producing Myo-Inositol and Myo-Inositol Derivative | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-07-07 | — | — | US | disclosed |
| US-9365603-B2 | Method for producing myo-inositol and myo-inositol derivative | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20140370549-A1 | Method for Producing Scyllo-Inositol | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140296497-A1 | Method for Producing Myo-Inositol and Myo-Inositol Derivative | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194667-A1 | Method for Producing Myo-Inositol and Myo-Inositol Derivative | ITPA, IPMK, PPIP5K2 | MEN1 421/4885KMT2A 1480/4885LGALS8 2716/4885 |
| US-20140296497-A1 | Method for Producing Myo-Inositol and Myo-Inositol Derivative | ITPA, IPMK, IMPA1 | MEN1 368/4885KMT2A 1730/4885LGALS8 2726/4885 |
| US-20140370549-A1 | Method for Producing Scyllo-Inositol | PPIP5K2, ITPA, IPMK | MEN1 2739/4885KMT2A 2883/4885LGALS8 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.